How Janney Capital Currently Rates Acceleron Pharma (NASDAQ:XLRN)
New York: Acceleron Pharma (NASDAQ:XLRN) coverage has been initiated with a Neutral rating by investment analysts at Janney Capital. This was disseminated in a recent research report on Thursday morning.
From a total of 7 analysts covering Acceleron Pharma (NASDAQ:XLRN) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 86% of the ratings are positive. The highest target price is $65 while the lowest target price is $45. The mean of all analyst targets is $57.29 with a 22.37% above today’s ($44.13) stock price. Acceleron Pharma was the topic of 2 analyst reports since August 13, 2015 according to the firm StockzIntelligence Inc. Oppenheimer initiated shares on November 20 with “Outperform” rating.
The stock increased 1.26% or $0.55 during the last trading session, striking $44.13. Approximately shares of stock traded hands. Acceleron Pharma Inc (NASDAQ:XLRN) has risen 38.51% since May 14, 2015 and is uptrending. It has outperformed by 40.78% the S&P500.
The overall sentiment of institutions has decreased to 1.07 in Q2 2015. Its down 0.93, from 2 in 2015Q2. The ratio turned negative, as 15 institutions have sold all the shares of Acceleron Pharma Inc that they owned while 31 funds have taken shares off the table. 7 funds have purchased shares for the first time while 42 added to their positions. These institutions now hold 31.13 million shares or 26.70% more than the 24.57 million shares they owned in 2015Q2.
The Fund Agtc Partners L.P. currently is holding shares equating to 97.39% of its total portfolio in Acceleron Pharma Inc representing a total of 530,919 shares. Another fund,Polaris Venture Management Co Iv Llc, is holding a total of 1.48 million shares equating to 64.78% of their holdings. Additionally, Foresite Capital Management I Llc has a 162,070 share stake in Acceleron Pharma Inc which represents 43.03% of their total portfolio. The Fund, Foresite Capital Management Ii Llc, based out of California, has also built up a stake in the stock, which represents a total of 1.5% of their total portfolio. Finally Alpinvest Partners B.V., a fund which is based in the state of Netherlands reported a total holdings of 25,194 shares.
Insider activity is a very important aspect to track on any stock. Going back to March 10, 2015, shareholders of Acceleron Pharma Inc have witnessed 0 insider purchases, and a total of 20 sales equating to a net activity of approximately $17.71 million . Sherman Matthew L sold 6,000 shares worth approximately $139,669. Knopf John L sold 19,000 shares worth approximately $463,288. Mclaughlin Kevin F sold 7,000 shares worth approximately $170,639. Quisel John D sold 5,500 shares worth approximately $183,425. The company insider Kumar Ravindra sold 33,000 shares worth $1.16 million.
Acceleron Pharma Inc. is a biopharmaceutical firm focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The company has a market cap of $1.45 billion. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta protein superfamily. It currently has negative earnings. By combining its discovery and development know-how, including its knowledge of the TGF-b superfamily, and its internal protein engineering and manufacturing capabilities, the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action.
According to Zacks Investment Research, “Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.”